Title:Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A
Combination Therapy for Asthma
Volume: 18
Issue: 2
Author(s): Alberto Papi*, Konstantinos Kostikas, Ivan Nikolaev and Ioannis Kottakis
Affiliation:
- Respiratory Medicine, University of Ferrara, Italy
Keywords:
Asthma, indacaterol, glycopyrronium, mometasone, combination therapy, Breezhaler®.
Abstract: Despite the wide range of available therapies, asthma remains uncontrolled in 40-65% of
patients for a number of different reasons. Treatment with an inhaled corticosteroid (ICS) is recommended
in the Global Initiative for Asthma 2021 report for patients across all asthma severities,
with treatment options combining an ICS with a long-acting β2-agonist (LABA) or a LABA and a
long-acting muscarinic antagonist (LAMA), depending on disease severity. Based on this, the availability
of a single inhaler fixed-dose ICS/LABA/LAMA combination is a major need in asthma
management. Indacaterol acetate/glycopyrronium bromide/mometasone furoate has been developed
as a once-daily inhaled asthma treatment that combines an ICS (mometasone furoate), a LABA (indacaterol
acetate), and a LAMA (glycopyrronium bromide) in a formulation delivered using the dry
powder inhaler Breezhaler®, for patients with uncontrolled asthma on medium- or high-dose
ICS/LABA. This article provides an overview of the different and complementary mechanisms of
action and the clinical effectiveness of the monocomponents of the indacaterol/glycopyrronium/
mometasone furoate fixed combination and highlights the benefits of using the three agents in combination
in patients with moderate and severe asthma.